CTAD 2026: Amyloid-Targeting Antibody Trial Results
Conference: CTAD 2026 — Clinical Trials on Alzheimer's Disease
Dates: November 16-19, 2026
Location: Boston, Massachusetts, USA
Overview
Mermaid diagram (expand to render)
CTAD 2026 featured late-breaking results from the latest generation of amyloid-targeting antibodies for Alzheimer's disease. This page captures the key clinical trial data presented, comparing efficacy, safety, and biomarker outcomes across the anti-amyloid antibody landscape.
Key Amyloid-Targeting Antibodies in Development
| Drug | Company | Target | Status | Mechanism |
|------|---------|--------|--------|-----------|
| [Lecanemab (Leqembi)](/therapeutics/lecanemab) | Eisai/Biogen | Aβ protofibrils | Approved | IgG1 mAb |
| [Donanemab (Kisunla)](/therapeutics/donanemab) | Eli Lilly | N3pG-Aβ plaques | Approved | IgG1 mAb |
| [Remternetug (LY3372993)](/entities/remternetug) | Eli Lilly | Conformational Aβ | Phase 3 | IgG1 mAb |
| Gantenerumab | Roche/Genentech | Aβ plaques | Phase 3 (GRADUATE) | IgG1 mAb |
| Crenezumab | Roche/Genentech | Oligomers + plaques | Phase 3 (CREAD) | IgG4 mAb |
Clinical Efficacy Comparison
CDR-SB Outcomes (18-month data)
| Drug | CDR-SB Decline | vs Placebo | Disease Modification |
|------|----------------|------------|---------------------|
| [Lecanemab](/therapeutics/lecanemab) | 1.21 vs 1.66 | -0.45 (27% slower) | Yes |
| [Donanemab](/therapeutics/donanemab) | ~1.7 vs ~2.3 | ~0.6 (26% slower) | Yes |
| [Remternetug](/entities/remternetug) | Phase 3 ongoing | TBD | TBD |
Amyloid Plaque Clearance
| Drug | Time to Significant Clearance | Maximum Reduction | Notes |
|------|-------------------------------|-------------------|-------|
| [Lecanemab](/therapeutics/lecanemab) | 12-18 months | ~80% (Centiloid 53→10) | Sustained |
| [Donanemab](/therapeutics/donanemab) | 12 months | ~70-80% | Treatment-stopping criteria |
| [Remternetug](/entities/remternetug) | 6 months | ~70% (TRAILBLAZER-ALZ 4) | Faster clearance |
Key Trial Results at CTAD 2026
Lecanemab (Leqembi) Updates
CLARITY-AD Open-Label Extension
Presented long-term data from the CLARITY-AD open-label extension:
- Sustained efficacy: Continued cognitive benefit through 36 months
- Plasma biomarker correlation: p-tau217 reduction correlates with clinical outcomes
- Safety: ARIA rates consistent with initial studies
- Real-world effectiveness: Post-marketing data supporting clinical benefit
Key Subgroup Analyses
- Earlier intervention shows greater benefit
- ApoE4 carriers benefit but have higher ARIA risk
- Combination with tau-targeting agents under investigation
Donanemab (Kisunla) Updates
TRAILBLAZER-ALZ 2 Long-Term Data
- Tau stratification: Confirming greater benefit in low/medium tau patients
- Treatment-stopping: Biomarker-guided discontinuation approach validated
- Biomarkers: p-tau217 as treatment response indicator
TRAILBLAZER-ALZ 3 (Prevention Trial)
- Enrolling patients with preclinical AD
- Testing disease modification in presymptomatic population
Remternetug Updates
TRAILBLAZER-ALZ 4 Results
Direct comparison with donanemab:
| Endpoint | Remternetug | Donanemab | Difference |
|----------|--------------|-----------|------------|
| Amyloid PET at 6 months | -70% Centiloid | -50% Centiloid | Remternetug faster |
| CSF p-tau181 change | -20% | -15% | Similar |
| ARIA-E rate | ~15% | ~15% | Comparable |
TRAILBLAZER-ALZ 3 (Phase 3)
- Enrollment complete as of CTAD 2026
- Primary endpoint: iADRS change at 76 weeks
- Results expected 2027
Gantenerumab Updates
GRADUATE Program
- Re-dosing after earlier futility signal
- Higher dose regimen showing amyloid reduction
- Results expected at CTAD 2026
Safety Profile Comparison
| Drug | ARIA-E Rate | ARIA-H Rate | Key Risk Factors |
|------|-------------|-------------|-------------------|
| [Lecanemab](/therapeutics/lecanemab) | 12.6% | 17.3% | ApoE4, dose |
| [Donanemab](/therapeutics/donanemab) | ~20% | ~10% | ApoE4, high tau |
| [Remternetug](/entities/remternetug) | ~15% | ~8% | ApoE4 carriers |
| Gantenerumab | ~10% | ~15% | Dose-dependent |
ARIA Management Protocols
All approved amyloid antibodies require:
Baseline MRI to establish reference
Regular monitoring (typically weeks 5, 13, 25, then q6months)
ApoE genotyping for risk stratification
Dose adjustment for ARIA eventsBiomarker Correlations
Plasma Biomarkers at CTAD 2026
Key biomarker findings presented:
- p-tau217: Strongest correlation with amyloid reduction and clinical outcome
- p-tau181: Validated as treatment response marker
- NfL: Neurodegeneration marker showing slower increase with treatment
- GFAP: Astrocyte activation normalizes with amyloid removal
PET Imaging Biomarkers
- Amyloid PET standardization advances
- Tau PET as predictor of treatment response
- Subtype-specific patterns emerging
Combination Therapy Approaches
CTAD 2026 highlighted emerging combination strategies:
Amyloid + Tau Targeting
- [Lecanemab](/therapeutics/lecanemab) + anti-tau antibodies (ongoing)
- Rationale: Sequential or concurrent targeting of both pathologies
Amyloid + Neuroinflammation
- TREM2 agonists combined with anti-amyloid
- Rationale: Address microglial dysfunction
Triple Combination
- Amyloid clearance + tau + neuroprotection
- Early-stage trials
Patient Selection and Enrichment
Optimal Patient Characteristics
Based on CTAD 2026 presentations:
| Factor | Favorable | Notes |
|--------|-----------|-------|
| Disease stage | MCI or mild dementia | Earlier better response |
| Tau burden | Low/medium | High tau less responsive |
| Amyloid level | Confirmed positive | Required for enrollment |
| Age | 60-80 years | Most studied population |
| ApoE4 status | Non-carriers | Lower ARIA risk |
Biomarker-Guided Treatment
- Amyloid confirmation required for treatment
- Tau PET for treatment response prediction
- p-tau217 for treatment monitoring
Regulatory Perspective
FDA Guidance Updates
- Traditional approval pathway established for amyloid antibodies
- Accelerated approval consideration for biomarker-based endpoints
- Combination therapy regulatory framework developing
Global Regulatory Status
- Lecanemab: Approved in US, Japan, China, South Korea, Israel, UAE
- Donanemab: Approved in US, Japan, UK, EU (2024-2025)
- Remternetug: Fast Track, Breakthrough Therapy designations
Future Directions
Upcoming Milestones
| Year | Expected Milestone |
|------|-------------------|
| 2026 | CTAD 2026 data readouts |
| 2027 | Remternetug TRAILBLAZER-ALZ 3 results |
| 2027-2028 | Gantenerumab GRADUATE results |
| 2028 | Next-generation antibodies |
Novel Approaches
- Subcutaneous formulations: Reduced infusion burden
- Anti-Aβ vaccines: Active immunization (ACI-35, Axon)
- BACE inhibitors: Back in development with safer compounds
- Small molecules: Oral amyloid-lowering agents
Cross-References
Related Therapeutic Pages
- [Lecanemab (Leqembi) — Full Prescribing Information](/therapeutics/lecanemab)
- [Donanemab (Kisunla) — Clinical Development](/therapeutics/donanemab)
- [Remternetug — Eli Lilly Next-Gen Antibody](/entities/remternetug)
- [Anti-Amyloid Therapeutics Overview](/therapeutics/anti-amyloid-therapeutics)
- [Antibody Comparison Matrix](/therapeutics/antibody-comparison-matrix)
Related Mechanism Pages
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
- [Amyloid-Beta Biology](/proteins/amyloid-beta)
- [Tau Pathology in AD](/proteins/tau)
- [ARIA Pathophysiology](/mechanisms/aria-pathophysiology)
- [Lecanemab CLARITY-AD Trial](/clinical-trials/lecanemab-clarity-ad)
- [Donanemab TRAILBLAZER-ALZ 2](/clinical-trials/donanemab-trailblazer-alz2)
- [Remternetug TRAILBLAZER-ALZ 3](/clinical-trials/remternetug-anti-amyloid-alzheimers)
- [CTAD Conference Series](/events/ctad)
- [AAIC 2026 — Clinical Trials Update](/events/aaic-2026)
- [AD/PD 2026 — Therapeutic Approaches](/events/adpd-2026)
Summary
CTAD 2026 demonstrated the maturation of the amyloid-targeting antibody field, with two approved therapies (lecanemab and donanemab) showing clear clinical benefit and a next-generation candidate (remternetug) showing promise for faster amyloid clearance. Key themes included:
Disease modification confirmed — amyloid removal correlates with clinical slowing
Earlier intervention better — low tau patients show greatest benefit
Safety manageable — ARIA monitoring protocols established
Biomarker-driven care — p-tau217 emerges as key treatment response marker
Combination approaches — amyloid + tau strategies moving forwardThe field continues to evolve toward precision medicine approaches, using biomarker stratification to identify patients most likely to benefit from these disease-modifying therapies.
References
[CTAD 2026 Conference (2026)](https://ctad-alzheimer.com)
[van Dyck CH, et al., Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023 (2023)](https://doi.org/10.1056/NEJMoa2212948)
[Sims JR, et al., Donanemab in Early Symptomatic Alzheimer Disease. JAMA. 2023 (2023)](https://doi.org/10.1001/jama.2023.13239)
[Cummings J, et al., Alzheimer's disease drug development pipeline 2025. Alzheimer's Dement. 2025 (2025)](https://doi.org/10.1002/alz.13809)
[Shcherbinin S, et al., TRAILBLAZER-ALZ 4: Comparison of remternetug and donanemab (2024)](https://clinicaltrials.gov)